Moreover, as expected from the existing differences between sexes in the expression of EGFR activating mutation [13,14], women with non-squamous NSCLC in the present study cohort received a first-line target therapy more than twice as frequently as men with non-squamous NSLCL. This evidence concerns the gene EGFR and non-small cell lung carcinoma.